🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The primary objective of the study is to assess the safety and tolerability...
Status
Completed
Location
Multiple Locations
Start Date
2015-07
Trial ID
NCT02516618
The primary objective of the study is to evaluate the efficacy of fasinumab...
Status
Terminated
Location
Regeneron Research Site
Start Date
2017-10-30
Trial ID
NCT03285646
The main objective of the trial is to evaluate the efficacy of fasinumab co...
Status
Completed
Location
Multiple Locations
Start Date
2016-01-26
Trial ID
NCT02620020
The objective of this exploratory study is to evaluate the cellular and con...
Status
Terminated
Location
Regeneron Research Site
Start Date
2019-04-08
Trial ID
NCT03949673
Treatments Being Tested
The objective of this study is to verify the superiority of 16 weeks of MT-...
Status
Completed
Location
Investigational Site
Start Date
2017-09-08
Trial ID
NCT03245008
Treatments Being Tested
This is a double-blind, prospective, randomized study in which patients wil...
Status
Completed
Location
Multiple Locations
Start Date
2009-08
Trial ID
NCT00944892
Primary objective was to demonstrate the activity of REGN475/SAR164877 in r...
Status
Terminated
Location
Sanofi-Aventis Investigational Site Number 840005
Start Date
2009-11
Trial ID
NCT01001715
Treatments Being Tested
The primary objective of the study is to evaluate the effect of fasinumab c...
Status
Completed
Location
Regeneron Study Site
Start Date
2018-10-15
Trial ID
NCT03691974
This is a phase 2, randomized, double-blind, parallel-group, single dose st...
Status
Completed
Location
Regeneron Investigational Site
Start Date
2009-11
Trial ID
NCT00991172
Treatments Being Tested
Primary objective was to demonstrate the activity of REGN475/SAR164877 in r...
Status
Terminated
Location
Sanofi-Aventis Investigational Site Number 840024
Start Date
2009-12
Trial ID
NCT01001923
Treatments Being Tested